Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively). RWJ-67657 shows no activity at p38γ and p38δ and shows a cardioprotective effect.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 228.00 | |
50 mg | In stock | $ 368.00 | |
100 mg | In stock | $ 593.00 | |
500 mg | In stock | $ 1,250.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively). RWJ-67657 shows no activity at p38γ and p38δ and shows a cardioprotective effect. |
Targets&IC50 | p38β:11 μM, p38α:1 μM |
In vitro | RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3]. |
In vivo | RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once per day for 7 consecutive days) shows an effective anti-inflammatory effect. EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke by both improving the functioning of endothelial progenitor cells and reducing inflammation [2][4]. |
Synonyms | JNJ 3026582 |
Molecular Weight | 425.5 |
Formula | C27H24FN3O |
CAS No. | 215303-72-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (293.77 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RWJ-67657 215303-72-3 MAPK p38 MAPK RWJ67657 RWJ 67657 Inhibitor JNJ3026582 JNJ 3026582 anti-tumor JNJ-3026582 p38α protective. Anti-inflammatory MCF-7 inhibit inflammation cardio p38β inhibitor